CA
MDGL icon

Clearstead Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Clearstead Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.37K Buy
+10
New +$5.12K ﹤0.01% 2173
2025
Q3 		– Sell
-14
Closed -$4.24K – 3179
2025
Q2 		$4.24K Sell
14
-42
-75% -$12.5K ﹤0.01% 2162
2025
Q1 		$18.5K Sell
56
-2
-3% -$657 ﹤0.01% 1443
2024
Q4 		$17.9K Buy
58
+14
+32% +$3.94K ﹤0.01% 1421
2024
Q3 		$9.34K Buy
+44
New +$11.3K ﹤0.01% 1594

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Clearstead Advisors's MDGL Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 10 shares worth $5.37K. The stake represents ﹤0.01% of the portfolio and ranks #2173 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in MDGL as recently as Q2 2025.

Clearstead Advisors first reported a position in MDGL in Q3 2024 and has held it in 5 quarters since. The position peaked at $18.5K in Q1 2025. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Clearstead Advisors held 10 shares of Madrigal Pharmaceuticals worth $5.37K as of Q2 2026.
  • Madrigal Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2173 holding.
  • Clearstead Advisors first reported a position in Madrigal Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • Clearstead Advisors's Madrigal Pharmaceuticals position peaked at $18.5K in Q1 2025.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.